GT Biopharma Inc
NASDAQ:GTBP
GT Biopharma Inc
Cash from Financing Activities
GT Biopharma Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
GT Biopharma Inc
NASDAQ:GTBP
|
Cash from Financing Activities
$6.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
31%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is GT Biopharma Inc's Cash from Financing Activities?
Cash from Financing Activities
6.3m
USD
Based on the financial report for Dec 31, 2023, GT Biopharma Inc's Cash from Financing Activities amounts to 6.3m USD.
What is GT Biopharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
31%
The average annual Cash from Financing Activities growth rates for GT Biopharma Inc have been -21% over the past three years , -9% over the past five years , and 31% over the past ten years .